Bioventix PLC (GB:BVXP)
LSE:BVXP
Want to see GB:BVXP full AI Analyst Report?
BVXP Stock Chart & Stats
1800.00 p
56.00 p(1.70%)
At close: 4:00 PM EST
1800.00 p
56.00 p(1.70%)
Day’s Range― - ―
52-Week Range1,300.00 p - 3,020.00 p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£80.99M
Enterprise Value82.21M
Total Cash (Recent Filing)£5.30M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)10.9
Beta0.69
Next Earnings
Oct 26, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend Yield8.33%
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.93
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsExceptionally high and consistent margins reflect durable competitive advantages in antibody performance and pricing power. Sustained margin levels support strong earnings retention, make the business resilient to modest volume swings, and underpin long-term cash returns to shareholders.
Conservative Balance Sheet (no Debt)Zero leverage provides durable financial flexibility to fund operations, R&D partnerships, or shareholder distributions without refinancing risk. High ROE with no debt signals efficient capital use and reduces solvency risk through industry cycles.
Strong Cash Generation / Cash ConversionHigh cash conversion means reported profits translate into real cash available for dividends, reinvestment or strategic deals. This persistent conversion ability supports sustainable distributions and funds continued antibody development without reliance on external capital.
Bears Say
Slowing Revenue MomentumA recent revenue and earnings decline interrupts multi-year growth and could signal weaker product demand or customer take-up. If this trend persists, it may erode the high-margin base, limit reinvestment capacity, and pressure long-term growth and returns.
Free Cash Flow Decline In 2025A near-term ~9% FCF drop reduces the cash buffer that supports dividends and strategic flexibility. While conversion remains high historically, continued FCF weakness would weaken the company’s ability to sustain payouts or invest in new antibody programs without altering capital allocation.
Market & Customer Exposure (incl. China)Reliance on a B2B model with concentrated customers and exposure to geographic pressures (notably China) increases earnings volatility risk. Structural market access or customer-specific issues could disproportionately affect revenues given the firm’s small employee base and specialized product lineup.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1300.00 p and its highest was 3020.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £80.99M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Oct 26, 2026 which is in 136 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Mar 30, 2026. The company reported 0.684 p earnings per share for the quarter, beating the consensus estimate of 0.516 p by 0.168 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 70 p which represents an annual dividend yield of 8.33%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate is 0.66.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.684 p in its last earnings report, beating expectations of 0.516 p. Following the earnings report the stock price went up 6.909%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth £59.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
65.83%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---